Sanofi Pasteur 2009 en eerder (v.a. 2005)
Grappig om nog eens terug te lezen, die koersdoelen! Het geloof in de doortastendheid van het management! Uitspraken (in het persbericht) dat in 2008 alles er klaar voor zou staan.
1 april 2005: As a result of the agreement, sanofi pasteur has announced that it will accelerate its PER.C6® influenza vaccine program. At the end of three years, Phase 1 and 2 clinical studies will be completed and Phase 3 will be underway. Pim F 2-5-09
HIERBIJ EEN RECAPITULATIE VAN DE HIER BOVEN GENOEMDE DRAADJES VAN 1-5-09
HHS Awards $97 Million Contract to Develop Cell Culture-Based Influenza Vaccine
Friday April 1 2005 , 9:55 am ET
- Effort Designed to Diversify and Accelerate Vaccine Production to Enhance Pandemic Preparedness
WASHINGTON, April 1 /PRNewswire/ -- HHS Secretary Mike Leavitt announced today that the Department has awarded a $97 million contract to Sanofi Pasteur to speed the production process for new influenza vaccines for the U.S. The five-year award supports the development of advanced techniques using a cell- based, rather than an egg-based, approach to producing influenza vaccines. The contract also calls for plans to establish a U.S.-based, cell cultured influenza vaccine manufacturing facility.
Cell-based influenza vaccines use mammalian cells to grow the influenza viruses used in the vaccine. Under this contract, Sanofi Pasteur, a part of the Sanofi Pasteur Group, will develop, scale-up, and manufacture clinical investigational lots of inactivated influenza vaccines using human cells. These vaccines will be tested in human clinical trials in adult, elderly, and pediatric populations within the U.S. In addition, Sanofi Pasteur will develop plans for a U.S. manufacturing facility capable of producing at least 300 million doses of a pandemic influenza vaccine using this technology.
Lijkt mij nieuws waar wij allemaal op hebben zitten wachten. 1 van de drie berichten dan, naast STAR en Ebola contract.
Published: 15:50 01.04.2005 GMT+2 /HUGIN /Source: Crucell N.V. /AEX: CRXL /ISIN: NL0000358562
AFM Completes Investi gation into Exercising of Options by Crucell Management
Leiden, The Netherlands, April 1, 2005 - The Netherlands Authority for the Financial Markets (AFM) has notified Crucell that its investigation into the exercise of options and the subsequent sale of shares on January 18, 2005 by certain members of Crucell's Management and Supervisory Boards has been completed.
The investigation indicated that insider trading did not occur.
MORE) Dow Jones Newswires
04-01-05 1014ET
DJ Crucell Partners With Sanofi-Aventis In $97M Flu Deal
Edited Press Release
AMSTERDAM (Dow Jones)--Dutch biotechnology company Crucell (CRXL) said Friday in a press statement that its partner Sanofi Pasteur, the vaccines business of the sanofi-aventis Group (SNY),has been awarded a $97M contract by the U.S. Department of Health and Human Services (HHS).
The objective of the contract is to accelerate the licensure in the U.S. of a PER.C6® based cell-culture influenza vaccine and vaccine manufacturing facility. Crucell will be a subcontractor for the program. Terms of the subcontracting agreement between Crucell and sanofi pasteur were not disclosed.
The project is part of the U.S. government's effort to increase influenza vaccine manufacturing capacity in the event of a pandemic or other influenza health emergency.
As a result of the agreement, sanofi pasteur has announced that it will accelerate its PER.C6® influenza vaccine program. At the end of three years, Phase 1 and 2 clinical studies will be completed and Phase 3 will be underway.
In addition, sanofi pasteur announced it will deliver to the HHS a feasibility plan for the construction of a U.S.-based and licensed cell-culture production plant for supplying up to 300 million monovalent influenza vaccine doses annually.
Under the terms of the contract, sanofi pasteur will accelerate the existing project in order to complete a detailed design approximately two years earlier than originally intended.
Sanofi pasteur will entirely refit a vaccine development facility for the project and design and test the process from small to mid-sized industrial scale. Lonza Biologics plc., a biotechnology contract manufacturer and subsidiary of The Lonza Group, will contribute to key activities related to the scale up to very large volumes of PER.C6® cell culture and engineering design of the production facility. The contract does not include the actual construction of the plant.
"We are very pleased that Crucell's PER.C6® cell line will be the platform for creating a new influenza vaccine," commented Crucell's CEO, Ronald Brus.
"Producing sufficient influenza vaccine in case of an influenza pandemic will require a flexible, large-scale manufacturing system that can produce all influenza virus strains," added Dr Jaap Goudsmit, Crucell's Chief Scientific Officer. "We are pleased that the U.S. government selected the PER.C6® production technology as well positioned to meet those requirements."
Company Web site: http